drugset / Trial / NCT04481256
TGF-β And PDL-1 Inhibition in Esophageal Squamous Cell Carcinoma Combined With Chemoradiation TheRapY
Recruiting
49 enrolled
Academic Medical Center - University of Amsterdam
Catharina Ziekenhuis Eindhoven · collabDeventer Ziekenhuis · collabElisabeth-TweeSteden Ziekenhuis · collabErasmus Medical Center · collabFrisius Medisch Centrum · collabInstitute Verbeeten · collabIsala · collabLeiden University Medical Center · collabRadiotherapeutic Institute Friesland · collabRadiotherapy Group Deventer · collabRijnstate Hospital · collabThe Netherlands Cancer Institute · collabUMC Utrecht · collabUniversity Medical Center Groningen · collabZiekenhuisgroep Twente · collab
NaSingle-groupOpen-labelTreatment
Summary
The primary objective of this study is to assess the feasibility of treatment with bintrafusp alfa combined with definitive chemoradiation (carboplatin, paclitaxel and radiation) in patients with squamous cell carcinoma of the esophagus or gastroesophageal junction.
Timeline
- Start
- 2020-11-11
- Primary completion
- 2025-09-01
- Completion
- 2030-09-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bintrafusp alfa | Protein / enzyme biologic | 2400 mg | Intravenous |
| Background | Carboplatin | Small molecule | — | Intravenous |
| Background | Paclitaxel | Small molecule | 50 mg/m2 | Intravenous |